trending Market Intelligence /marketintelligence/en/news-insights/trending/f4UciyoAdF1dgR-Sxv_hzw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Impression Healthcare completes A$5M placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Impression Healthcare completes A$5M placement

Impression Healthcare Ltd. is raising A$5 million via a placement to fund its development of cannabinoid products for certain disorders.

The placement was conducted by Peloton Capital — acting as lead manager — at 7.8 Australian cents per share.

Australia-based Impression Healthcare plans to use proceeds to fast track the development of cannabinoid products for traumatic brain injury, sleep apnea and temporomandibular joint disorder. The company is planning early-stage trials for the three programs.

Part of the proceeds will be used to increase wholesale medicinal cannabis product purchases for distribution, to continue the development of its Incannex cannabidiol oils and to fund cannabinoid customer research and acquisition. Funds will also be used to appoint scientific or medical operation staff, to expand its oral devices in Australia and internationally, and to fund general working capital.

Impression Healthcare develops medical cannabis products, and it also manufactures and distributes custom-fit dental products.